Dose escalation study of Olaparib in addition to cisplatin based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (HNSCC)
| ISRCTN | ISRCTN62346992 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN62346992 |
| EudraCT/CTIS number | 2010-023599-24 |
| Secondary identifying numbers | 11024 |
- Submission date
- 28/10/2011
- Registration date
- 28/10/2011
- Last edited
- 16/10/2012
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Miss Dymphna Lee
Scientific
Scientific
Cancer Research UK & UCL Cancer Trials Centre
90 Tottenham Court Road
London
W1T 4TJ
United Kingdom
| ORCA@ctc.ucl.ac.uk |
Study information
| Study design | Non-randomised; Interventional; Design type: Treatment |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please contact ORCA@ctc.ucl.ac.uk to request a patient information sheet |
| Scientific title | A phase I/II study of Olaparib in addition to cisplatin based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (HNSCC) |
| Study acronym | ORCA |
| Study objectives | Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer in the world, accounting for >7500 of recorded cases in the UK (2006 data). Currently the standard treatment for high risk locally advanced HNSCC is cisplatin chemotherapy alongside high dose radiotherapy, however local recurrence rates are high at approximately 80%. This means there is a real need to look at improving local disease control in this group of patients. The purpose of this Phase I trial is to assess how olaparib, a Poly (ADP-ribose) polymerase (PARP) inhibitor is tolerated when added to standard chemoradiotherapy (CRT) treatment. This is a dose escalation trial which aims to find out the recommended dose and the best dosing schedule for olaparib in combination with cisplatin based CRT. Patients will be recruited from sites in the UK and the total number recruited will depend on the outcome of the dose escalation (expected to be around 40). This study is funded by Cancer Research UK and Astra Zeneca. A placebo controlled, randomised Phase II trial will follow once the recommended dose of olaparib has been established. |
| Ethics approval(s) | London City and East REC, ref:11/LO/1618 approval pending |
| Health condition(s) or problem(s) studied | Topic: National Cancer Research Network; Subtopic: Head and Neck Cancer; Disease: Head and Neck |
| Intervention | The patient numbers in this dose escalation phase I are estimated and will depend on the frequency and severity of adverse events. A modified continual reassessment method (mCRM) design will be used to maximise the information gathered across different cohorts. We aim to minimise patient delay by enrolling patients in parallel into all cohorts within the same dose band. This is a single arm study. The trial treatment will involve 2 cycles of induction chemotherapy which will consist of cisplatin and 5-FU (fluorouracil) chemotherapy. This will be followed by olaparib plus cisplatin based chemoradiotherapy for a further 7 weeks. Induction chemotherapy (6 weeks) Cisplatin 80mg/m2 i.v. on day 1 and 5-FU 1000mg/m2/day i.v. on day 1-4 (continuous infusion) of a 21 day cycle Chemoradiotherapy (8 weeks) Cisplatin will be given at a dose of 35mg/m2 i.v. on day 1 of each week and radiotherapy of 70Gy in 2Gy fractions on day 1-5. Olaparib will be started one week prior to chemoradiotherapy and continued until the end of chemoradiotherapy. This trial involves a dose escalation of olaparib. The first cohort dose will be 25mg bd (twice daily) for 3 consecutive days, and the maximum dose cohort will be 125mg bd for 5 consecutive days. Patients will be allocated the next available cohort upon entering the study. Total duration of treatment for this study is 14 weeks, and the follow up is for 2 years post end of treatment. As of 29/05/2012, the the above study was closed early due to issues surrounding the development and formulation of olaparib. No patients were recruited. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase I/II |
| Drug / device / biological / vaccine name(s) | Olaparib |
| Primary outcome measure | To assess the frequency of Dose Limiting Toxicities (DLTs) and adverse events. |
| Secondary outcome measures | 1. Other efficacy endpoints: complete response rate (cRR) 2. Time to loco-regional and any progression |
| Overall study start date | 01/12/2011 |
| Completion date | 01/12/2015 |
| Reason abandoned (if study stopped) | Lack of staff/facilities/resources |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | Planned Sample Size: 60; UK Sample Size: 60; |
| Key inclusion criteria | 1. Histologically confirmed high risk locally advanced HNSCC (TNM staging T(any) N2 or N3 M0, bulky T3 or T4 N(any) M0) who would normally be offered cisplatin-based radical chemoradiotherapy 2. Estimated life expectancy of at least 12 weeks 3. WHO performance status of 0 or 1 4. Aged more than or equal to 18 years 5. Adequate organ function: 5.1. Absolute neutrophils =1.5 x 10*9/L 5.2. Platelets =100 x 10*9/L 5.3. Haemoglobin =10g/dl (to be maintained above 12g/dl whilst on CRT treatment) 5.4. Creatinine =1.5 x ULN 5.5. Glomerular filtration rate (GFR) =60 ml/min 5.6. Serum bilirubin = 1.25 x ULN 5.7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) = 2.5 x ULN 6. Patients willing to use contraception for the duration of the trial and for six months post treatment 7. Able to give informed consent 8. Patient is willing and able to comply with the protocol for the duration of the study, including the treatment plan investigations required and follow up visits; Target Gender: Male & Female ; Lower Age Limit 18 years |
| Key exclusion criteria | 1. Head & neck cancers of the following types: Nasopharyngeal and paranasal sinus tumours, oral cavity tumours (tumours of the oral cavity) 2. Human Papilloma Virus positive oropharyngeal tumours (tonsillar and tongue base tumours) 3. Confirmed distant metastatic disease 4. Previous chemotherapy or radiotherapy for the treatment of HNSCC tumour 5. Previous therapy with a PARP inhibitor 6. Previous chemotherapy, immunotherapy or radiotherapy within the last 28 days prior to registration 7. Prior history of malignancy, except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, breast or prostate, and unless the patient has been free of malignancy for a period of 3 years prior to first dose of trial drug 8. Women who are pregnant or lactating 9. Pre-existing gastrointestinal disorders that may interfere with the delivery or absorption of trial drugs 10. Peripheral neuropathy > Grade 2 (lower grade neuropathy considered significant by treating clinician may be considered an exclusion criterion) 11. Significant hearing difficulties (patients with mildly impaired hearing must be made aware of potential ototoxicity) 12. Any serious and/or unstable pre-existing medical, psychiatric or other condition that, in the treating clinicians judgement, could interfere with patient safety or obtaining informed consent 13. Known hepatitis B or C infection 14. Immunocompromised patients [e.g. Known human imunodeficiency virus (HIV) positive status] 15. Active uncontrolled infection 16. The current use of drugs which are known to inhibit Cytochrome P450 3A4 (CYP3A4) which cannot be discontinued for the duration of trial treatment |
| Date of first enrolment | 01/12/2011 |
| Date of final enrolment | 01/12/2015 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Cancer Research UK & UCL Cancer Trials Centre
London
W1T 4TJ
United Kingdom
W1T 4TJ
United Kingdom
Sponsor information
University College London (UK)
University/education
University/education
Gower Street
London
WC1E 6BT
England
United Kingdom
"ROR" |
https://ror.org/02jx3x895 |
|---|
Funders
Funder type
Industry
AstraZeneca (UK)
Government organisation / For-profit companies (industry)
Government organisation / For-profit companies (industry)
- Alternative name(s)
- AstraZeneca PLC, Pearl Therapeutics
- Location
- United Kingdom
Cancer Research UK (CRUK) (UK)
Private sector organisation / Other non-profit organizations
Private sector organisation / Other non-profit organizations
- Alternative name(s)
- CR_UK, Cancer Research UK - London, CRUK
- Location
- United Kingdom
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 28/06/2023 | No | No |
